Targets › TRHR
1 program from 1 company in 1 trial: 1 Phase 3; Neurology; next expected readout Mar 2027.
Receptor for thyrotropin-releasing hormone (TRH). Upon ligand binding, this G protein-coupled receptor triggers activation of the phosphatidylinositol (IP3)-calcium-protein kinase C (PKC) pathway. (UniProt, P34981)
Open in Phaseline: the race on TRHR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Kissei Pharmaceutical | Rovatirelin (KPS-0373) Thyrotropin-releasing hormone receptor agonist | TRHR | Phase 3 | Spinocerebellar Degeneration | Mar 2027 |
Spinocerebellar Degeneration (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.